Literature DB >> 29843157

Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Fatemeh G Amlashi1, Xuemei Wang2, Raquel E Davila3, Dipen M Maru4, Manoop S Bhutani3, Jeffrey H Lee3, Brian R Weston3, Dilsa Mizrak Kaya1, Maria Vassilakopoulou1, Kazuto Harada1, Mariela A Blum Murphy1, David C Rice5, Wayne L Hofstetter5, Marta Davila3, Quynh-Nhu Nguyen6, Jaffer A Ajani1.   

Abstract

INTRODUCTION: Barrett's esophagus (BE) may be present in patients with esophageal adenocarcinoma (EAC) after bimodality therapy (BMT). There is no specific guidance for follow-up of these patients with regard to the presence of BE or dysplasia. In this study, we assessed the outcomes of patients who, after BMT, had BE and those who did not.
METHOD: Patients with EAC who had BMT were identified and analyzed retrospectively in two groups, with and without BE. We compared patient characteristics and outcome variables (local, distant, and no recurrence).
RESULTS: Of 228 patients with EAC, 68 (29.8%) had BE before BMT. Ninety-eight (42.9%) had BE after BMT, and endoscopic intervention was done in 11 (11.2%). With a median follow-up of 37 months, the presence of post-BMT BE was not significantly associated with overall survival (OS) and local recurrence-free survival (LRFS). Similarly, endoscopic intervention was not significantly associated with OS and LRFS. Fifty (73.5%) patients with BE before BMT had BE after BMT (p < 0.0001).
CONCLUSION: The presence of BE after BMT was not associated with increased risk of local recurrence. The local recurrence rate was not influenced by endoscopic intervention. Prospective studies are warranted to generate guidance for intervention, if necessary, for this group of EAC patients.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Barrett’s esophagus; Endoscopy; Esophageal adenocarcinoma; Recurrence; Survival

Mesh:

Year:  2018        PMID: 29843157      PMCID: PMC6067962          DOI: 10.1159/000488489

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  39 in total

Review 1.  Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?

Authors:  Abraham J Wu; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Authors:  M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema
Journal:  Am J Gastroenterol       Date:  2011-05-17       Impact factor: 10.864

3.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

4.  Patterns of recurrence after trimodality therapy for esophageal cancer.

Authors:  Jennifer A Dorth; John A Pura; Manisha Palta; Christopher G Willett; Hope E Uronis; Thomas A D'Amico; Brian G Czito
Journal:  Cancer       Date:  2014-04-07       Impact factor: 6.860

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?

Authors:  James S Barthel; Stephen T Kucera; James L Lin; Sarah E Hoffe; Jonathan R Strosberg; Irfan Ahmed; Thomas J Dilling; Craig W Stevens
Journal:  Gastrointest Endosc       Date:  2009-12-08       Impact factor: 9.427

7.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

Review 9.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions.

Authors:  Christopher P Wild; Laura J Hardie
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

10.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Authors:  Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker
Journal:  Gut       Date:  2013-10-28       Impact factor: 23.059

View more
  1 in total

1.  Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.

Authors:  Mimi C Tan; Nabil Mansour; Donna L White; Amy Sisson; Hashem B El-Serag; Aaron P Thrift
Journal:  Aliment Pharmacol Ther       Date:  2020-05-26       Impact factor: 8.171

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.